Global Health Investment Corporation

Global Health Investment Corporation, founded in 2012 and based in New York City, is an investment fund dedicated to advancing technologies that enhance human health globally. The organization provides financing to support the development of drugs, vaccines, diagnostics, and other interventions targeting critical health challenges. It has a strong focus on late-stage innovations aimed at combating infectious diseases and addressing maternal and infant health issues, which significantly contribute to morbidity and mortality in resource-limited settings. The fund has been involved in projects related to conditions such as postpartum hemorrhage, malaria, cataracts, cholera, HIV, and river blindness. To achieve its goals, the corporation employs various investment structures, including preferred equity, convertible debt, and project financing.

Justine Potemkin

Associate

Tracy Saxton

Venture Partner

Damien Soghoian Ph.D

Venture Partner

10 past transactions

Micron Biomedical

Series A in 2025
Micron Biomedical is a clinical-stage biopharmaceutical company founded in 2014 and based in Atlanta, Georgia. The company focuses on developing innovative microneedle patches designed for administering vaccines, specifically targeting influenza and polio. Its proprietary microneedle technology aims to enhance the protective and therapeutic effects of vaccines while improving patient compliance and simplifying the administration process. Through its advanced delivery methods, Micron Biomedical seeks to facilitate the development of vaccines that can address critical healthcare needs.

CytoVale

Series D in 2024
CytoVale, Inc. is a medical technology company based in San Francisco, California, that specializes in developing innovative biomarkers utilizing the mechanical properties of individual cells, a field known as mechanomics. Founded in 2013, the company employs microfluidics technology to effectively route and physically probe single cells, allowing for the simultaneous measurement of multiple biomarkers. This approach aims to enhance early detection and diagnosis of immune-mediated diseases, particularly sepsis. By leveraging cell mechanics and machine learning, CytoVale seeks to revolutionize the diagnostic landscape, ultimately improving patient outcomes and reducing treatment costs in healthcare.

Vaxess Technologies

Venture Round in 2024
Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company specializes in the development and commercialization of silk biomaterial technologies, particularly the MIMIX microneedle platform, which facilitates transdermal delivery of vaccines and therapeutics. This innovative sustained release patch technology enhances vaccine administration by simulating a natural infection, promoting a robust and prolonged immune response, thereby improving vaccine effectiveness. Additionally, Vaxess’s MATRIX formulation and drying platform creates thermostable vaccines, therapeutics, and diagnostic products that do not require refrigeration, making them suitable for distribution in low-resource settings. Through these advanced solutions, Vaxess aims to improve patient outcomes in oncology care and infectious diseases while reducing treatment burdens for healthcare practitioners.

Biolinq

Venture Round in 2024
Biolinq Inc. is a San Diego-based company specializing in the development of innovative skin-applied electronic sensors designed to analyze body fluids and deliver health insights. Founded in 2012, Biolinq focuses on creating a digital health platform that facilitates biomonitoring solutions. Its flagship product is a minimally invasive electrochemical biosensor that continuously monitors various biomarkers in interstitial fluid, including glucose, ketones, and lactate. This technology enables diabetic patients to track their blood glucose levels without the discomfort associated with traditional monitoring methods. By providing actionable health information and insights, Biolinq aims to enhance metabolic health and improve the quality of life for individuals managing diabetes.

CytoVale

Series C in 2023
CytoVale, Inc. is a medical technology company based in San Francisco, California, that specializes in developing innovative biomarkers utilizing the mechanical properties of individual cells, a field known as mechanomics. Founded in 2013, the company employs microfluidics technology to effectively route and physically probe single cells, allowing for the simultaneous measurement of multiple biomarkers. This approach aims to enhance early detection and diagnosis of immune-mediated diseases, particularly sepsis. By leveraging cell mechanics and machine learning, CytoVale seeks to revolutionize the diagnostic landscape, ultimately improving patient outcomes and reducing treatment costs in healthcare.

Vaxess Technologies

Venture Round in 2023
Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company specializes in the development and commercialization of silk biomaterial technologies, particularly the MIMIX microneedle platform, which facilitates transdermal delivery of vaccines and therapeutics. This innovative sustained release patch technology enhances vaccine administration by simulating a natural infection, promoting a robust and prolonged immune response, thereby improving vaccine effectiveness. Additionally, Vaxess’s MATRIX formulation and drying platform creates thermostable vaccines, therapeutics, and diagnostic products that do not require refrigeration, making them suitable for distribution in low-resource settings. Through these advanced solutions, Vaxess aims to improve patient outcomes in oncology care and infectious diseases while reducing treatment burdens for healthcare practitioners.

Micron Biomedical

Series A in 2022
Micron Biomedical is a clinical-stage biopharmaceutical company founded in 2014 and based in Atlanta, Georgia. The company focuses on developing innovative microneedle patches designed for administering vaccines, specifically targeting influenza and polio. Its proprietary microneedle technology aims to enhance the protective and therapeutic effects of vaccines while improving patient compliance and simplifying the administration process. Through its advanced delivery methods, Micron Biomedical seeks to facilitate the development of vaccines that can address critical healthcare needs.

Centivax

Seed Round in 2022
Centivax is a healthcare-focused company that specializes in biotechnology and therapeutic services. It has developed a universal vaccine platform aimed at treating and eradicating rapidly mutating pathogens. Utilizing its expertise in computational immune engineering, Centivax works on creating therapeutic monoclonal antibodies targeting various pathogens. Notably, the company has built a panel of neutralizing antibodies against SARS-CoV-2, contributing to public health safety through its vaccination efforts.

Vaxess Technologies

Series B in 2022
Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company specializes in the development and commercialization of silk biomaterial technologies, particularly the MIMIX microneedle platform, which facilitates transdermal delivery of vaccines and therapeutics. This innovative sustained release patch technology enhances vaccine administration by simulating a natural infection, promoting a robust and prolonged immune response, thereby improving vaccine effectiveness. Additionally, Vaxess’s MATRIX formulation and drying platform creates thermostable vaccines, therapeutics, and diagnostic products that do not require refrigeration, making them suitable for distribution in low-resource settings. Through these advanced solutions, Vaxess aims to improve patient outcomes in oncology care and infectious diseases while reducing treatment burdens for healthcare practitioners.

Univercells

Series D in 2022
Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.